Last updated: November 12, 2026
By Dave Manchester, Scientific Recruiting, KORE1
Can contract regulatory affairs staff help you hit an NDA or BLA submission date? Yes, if strategy, agency contact and sign-off stay with your regulatory lead and the contractors take the volume, meaning CMC drafting, eCTD publishing, document QC and information-request responses. KORE1 contract placements start a median 3 days after offer (n=1,997, all roles). Data as of October 2026.
I recruit scientific staff for KORE1’s life sciences staffing practice. That means I get paid when you hire through us. So read what follows with that in the back of your mind. Every regulation I mention is linked to its source, because I would rather you check me than trust me.
For the bigger picture on contract and permanent seats at a pharma site, the pharmaceutical staffing page is the better starting point.
And this post sticks to one narrow situation, a filing date that will not move and a team that does not have enough hands.
What Breaks If the Submission Date Slips?
Devin Hornick, a partner at KORE1, has a question he asks about any funded project, and it is the one I’d put to a head of regulatory with a filing date on the calendar. “What breaks if the company doesn’t spend the money or finish the project?” With a submission date plugged into that sentence, the answers get concrete quickly.
Take an IND, the investigational new drug application that lets a sponsor begin clinical trials. It goes into effect 30 days after FDA receives it unless FDA places a clinical hold or tells you sooner that you can proceed (21 CFR 312.40(b)), so a package that arrives three weeks late moves first dosing by three weeks, and everything scheduled behind first dosing moves with it. An NDA, a new drug application, has a longer chain. FDA decides within 60 days whether to file it, and the review goal runs from there. Your commercial team has probably built a launch plan backward from both. Not every slip matters that much. Three days of drift costs you an awkward meeting. The ones that hurt tend to share a profile, though. The science is done, the strategy is agreed, and the only thing between you and the filing is a pile of assembly work. That happens to be what contractors are good for.
Which Submission Tasks Can a Contractor Take?
The way I’d split it is by who has to answer for the work. Judgment stays with your regulatory lead and volume goes to contractors. Devin describes the buyer’s side of any contract engagement in nearly those terms.
“This is just a hiring manager with a budget, going outside and hiring something and saying, I have this to get done and I need you to do it.” Your version of that sentence includes a filing date, and the table below sorts the tasks.
| Submission task | Contract-ready or keep internal | Why |
|---|---|---|
| Regulatory strategy (pathway, expedited programs, what goes in the filing) | Keep internal | Your company answers for these decisions, and somebody who joined three weeks ago hasn’t built the judgment or the standing to make them. |
| Agency meetings and correspondence | Keep internal | FDA ought to hear from a named person who will still be at your company after the filing, although a contractor can draft sections of a briefing package and take minutes in the meeting. |
| Module 1 (regional administrative content, such as the application form and cover letter) | Contract-ready, your signature | The applicant has to submit a completed and signed application form (21 CFR 314.50(a)), so a contractor can assemble it and your authorized signer takes it from there. |
| Module 3 CMC drafting (chemistry, manufacturing and controls) | Contract-ready, if the source reports exist | Finished batch, stability, and validation reports can be written up by someone who wasn’t in the lab, but missing data can’t be written up by anybody, and your CMC lead still owns every claim. |
| eCTD publishing and validation | Contract-ready | Probably the cleanest handoff on the list, since it needs tool access and a style guide more than it needs company history, and FDA names eCTD as the standard format for NDAs, ANDAs, BLAs, and commercial INDs. |
| Document QC (cross-references, bookmarks, numbers that agree across modules) | Contract-ready | Fresh eyes catch the cross-reference the author stopped seeing around draft three. |
| Labeling | Split | FDA negotiates the wording with your regulatory lead, but formatting and structured-format conversion can go to a contractor. |
| Information-request responses | Contract-ready for drafts, keep the sign-off | Drafting is volume work, though the answer FDA reads speaks for your company, so your lead approves it before it goes out. |
The split is my read, not an FDA rule, and your regulatory lead and quality group get the final vote. The source for the eCTD row is FDA’s eCTD page (content current as of October 29, 2026), which lists noncommercial INDs as optional but encouraged. Regulation text was read on Cornell’s Legal Information Institute mirror on November 11, 2026.
Let’s Connect. If you tell me the submission type and date and which tasks you are short on, I can tell you whether it is a fit, so send me the submission along with the modules or tasks you need covered, the publishing tool your team uses, and whether the work is remote or onsite.
Information requests are the row I would watch, because they arrive after you have filed and on FDA’s schedule instead of yours.
In its PDUFA VII commitment letter, FDA describes a four-part structure for CMC requests (what was provided, what the issue is, what’s needed and why it is needed), so a contractor handed a request in that shape can draft the reply while your CMC lead keeps working on the science.
Which Clocks Are You Working Against?
I’d pull the regulation itself rather than trust anybody’s summary, mine included, so each item below links to its source, and I checked every one on November 11, 2026.
- An IND goes into effect 30 days after FDA receives it, unless FDA imposes a clinical hold or tells you earlier that you can begin (21 CFR 312.40(b)).
- For an NDA, FDA has 60 days from receipt to decide whether it can be filed at all, which is a threshold check that the application is complete enough for a substantive review (21 CFR 314.101(a)). One of the listed reasons for refusing to file is an application that is not in the form 21 CFR 314.50 requires, so formatting mistakes can carry real weight.
- Under the PDUFA VII commitment letter, FDA aims to act on 90 percent of standard NME NDAs (new molecular entities) and original BLAs within 10 months of the 60-day filing date, or within 6 months if the review is priority, while standard non-NME original NDAs get the same 10 and 6 months counted from receipt.
- In the PDUFA review program for NME NDAs and original BLAs, filing review issues come back in the Day 74 letter, which FDA sends within 74 calendar days of receipt.
- A major amendment can push the goal date out by three months, and each review cycle allows one such extension.
Nothing on that list starts when your team feels ready. Each of those clocks starts when FDA receives the package, and a goal date is FDA’s own performance target, measured against 90 percent of applications, so it is not a promise made to you. BLAs sit under a separate regulation that I haven’t cited here, and the PDUFA goals only treat original BLAs like NME NDAs, which is why they appear above.
So how fast can a contractor help? KORE1 contract placements start a median 3 days after the offer, and three-quarters start within 5 days (n=1,997, all roles). That’s offer to start. It leaves out the search that comes before the offer.
And KORE1 has no regulatory affairs line in its placement data. So I have no regulatory-specific figure for either number and I will not guess one.
How Do You Brief Contract Regulatory Staff in Week One?
Ask for access before the first day, because seats in a regulatory information management (RIM) system or a publishing tool such as Veeva Vault RIM or Lorenz docuBridge don’t appear on their own, and a publisher with no login is a very well-paid observer.
- The style guide and templates your last submission used, since contractors match whatever they’re shown.
- Prior agency correspondence and meeting minutes, which tell the contractor what FDA already said and what you promised in return.
- The submission plan, meaning every module with its owner and its due date.
- The review cycle, meaning who reads a draft, how many days they get with it, and who settles a disputed edit. Leave this out and the review loop will eat the schedule you hired help to protect.
Then tell them plainly what they’re not doing. A contractor who knows strategy is not theirs won’t drift into it, and your regulatory lead won’t have to take it back in week four.
What Does Contract Regulatory Help Cost?
I don’t have a number to give you, and I’d rather say that than invent one. KORE1 has no regulatory affairs rate in its Contract Rate Index, so what you get is a quote built for the seat, billed hourly, with the rate covering wages, payroll taxes, workers’ compensation, liability insurance, paid sick leave, and the firm’s margin, so the invoice shows one figure with everything inside it. A package price for a whole submission is a consulting model, and KORE1 doesn’t work that way.
Budget in hours. Ten weeks at 40 hours is 400 hours per person, two people come to 800, and your quote supplies the multiplier.
For the model itself, our contract staffing page lays out how an engagement runs, and contract staffing rates shows the bill rates KORE1 does publish, by role, level, and metro, though regulatory affairs is not one of its rows.
After the Filing, Do You Keep, Convert or Release?
The work does not stop on submission day, because review runs for months, filing review comments come back, and information requests come in, so who you keep depends on which of those you expect to be heavy. I’d release the publishers once the sequence is in and nothing is queued behind it. I’d keep the CMC writer through the filing review if you think reviewers will ask about manufacturing. And I’d convert somebody only when their knowledge of your files is worth more than the open requisition. That is the one case where a permanent seat beats a contract.
Here’s the arithmetic on that. A KORE1 contractor can convert to your payroll at no fee after 1,040 hours, about 26 weeks at 40 hours a week, while the median ended assignment at KORE1 runs 116 days, 16 weeks (n=1,887, all roles), so a typical assignment finishes before the no-fee point and I would plan on release unless you start with contract-to-hire in mind. Of KORE1’s contract-to-hire placements, 37.5% did convert to direct hire (207 of 552), a figure that covers every role family together. If you land on a permanent hire, contract-to-hire vs direct hire cost works through the math, and contract-to-hire conversion rates explains which conversion number answers which question. Safety reporting runs on clocks of its own, and the pharmacovigilance staffing page covers that side.
Source: KORE1 placement data, 2019 to 2026, W2 contract placements, exported October 16, 2026. Offer to start n=1,997, median 3 days, 75th percentile 5 days. Assignment length n=1,887 ended assignments, median 116 days. The wider dataset is 79% California. Anomalies and payroll-service deals are excluded. None of these figures is regulatory-specific.
What Regulatory Leads Ask
Can I bring in contract regulatory affairs staff to hit an NDA or BLA submission date?
For the volume work, yes. Keep strategy, agency contact and sign-off in-house, and contract CMC drafting, eCTD publishing, document QC and information-request drafts.
The table above sorts each task. And the rule of thumb is that anything your company has to answer for stays with your regulatory lead.
Do contractors change who is responsible for the application?
No. The application is your company’s, and the signed application form comes from you, as 21 CFR 314.50(a) requires of the applicant.
Contractors prepare and you submit. If a contract with a specific vendor raises questions about responsibility, that is a conversation for regulatory counsel and not for a recruiter.
Does FDA require eCTD for my submission?
Usually. FDA says eCTD is the standard format for NDAs, ANDAs, BLAs, and commercial INDs, while noncommercial INDs are optional but encouraged.
Submissions must use a version FDA currently supports, either v3.2.2 or v4.0, and FDA’s page says forward compatibility is supported from October 16, 2026, so check the page before you settle on a publishing approach.
How soon could a contractor actually start?
Three days is the median from offer to start at KORE1 (n=1,997, all roles), but that clock starts at the offer.
The search comes first. And I have no regulatory-specific number for it.
What happens to the contractors once we file?
You pay for hours worked, so when the assignment ends the invoices end, and a contractor can convert to your payroll at no fee after 1,040 hours.
KORE1 contracts carry no replacement guarantee. What you get is a contractor who shows up on time and is paid on Fridays, and the option to hire them after the no-fee point.
Tell Me the Submission
Five details get you an answer. The submission type, the target date, the modules or tasks you are short on, your publishing tool, and whether the work is remote or onsite. When you are ready, Let’s Connect. Expert in finding you the right talent, right away.
You can also find me on LinkedIn.
